Lisa Morere

MCL-178: Clinical Outcomes Among Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Zanubrutinib or Acalabrutinib in Real-World Practice in the United States

Jing‐Zhou Hou, Javier Muñoz, Gregory Maglinte, Manasi Suryavanshi et autres

us, py (code pays fourni par la source)

POSTER: MCL-178: Clinical Outcomes Among Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Zanubrutinib or Acalabrutinib in Real-World Practice in the United States

Jing‐Zhou Hou, Javier Muñoz, Gregory Maglinte, Manasi Suryavanshi et autres

us, py (code pays fourni par la source)

Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia

Jing‐Zhou Hou, Rushir Choksi, Gregory A. Maglinte, Xiaoliang Wang et autres

Introduction Second-generation covalent Bruton tyrosine kinase inhibitors (cBTKi), acalabrutinib and zanubrutinib, are standard-of-care for treatment-naïve adults with chronic lymphocytic leukemia (CLL). However, real-world evidence remains limited.Methods This real-world analysis compared acalabrutinib and zanubrutinib using the IntegraConnect PrecisionQ de-identified electronic health record database, …

us, ar, ch (code pays fourni par la source)

Quality initiative in first-line multiple myeloma assessing the use of anti-CD38 agents and quadruplet therapy

Joseph K. Franz, Dhaval R. Mehta, Kathleen Anne Dorritie, Rushir J. Choksi et autres

Abstract Background: The University of Pittsburgh Medical Center (UPMC) partnered with IntegraConnect to conduct a quality initiative (QI) studying the utilization of anti-CD38 agents and quadruplet (quad) therapy (lenalidomide, CD38, proteasome inhibitor and dexamethasone) in newly diagnosed multiple myeloma (NDMM), and how …

us, ca (code pays fourni par la source)

Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia

Jing-Zhou Hou, Rushir J. Choksi, Gregory A. Maglinte, Xiaoliang Wang et autres

Abstract Background The use of targeted therapies, such as combinations of anti-CD20 monoclonal antibodies and BCL2 inhibitors, is rapidly evolving in the treatment of chronic lymphocytic leukemia (CLL). Venetoclax plus obinutuzumab (VO) is approved as a first-line (1L) therapy with a fixed …

us, py, ca (code pays fourni par la source)

Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy

Jing-Zhou Hou, Rushir J. Choksi, Gregory A. Maglinte, Xiaogang Wang et autres

Abstract Background Bruton tyrosine kinase (BTK) inhibitors have demonstrated clinical efficacy in treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Zanubrutinib is a highly specific and potent next-generation BTK inhibitor designed to maximize BTK occupancy and limit off-target kinase binding. In head-to-head trials, …

us, py, ca (code pays fourni par la source)

Initial performance of pirtobrutinib: Real-world outcomes among CLL patients after prior covalent-BTKi and BCL2i use

Rushir J. Choksi, Aliakbar Dadla, Thomas Weart, Brian Patrick Mulherin et autres

Abstract Background: Non-covalent Bruton's tyrosine kinase inhibitors (BTKi) are third-generation BTKis that utilize non-covalent bonding to improve efficacy and safety by reducing unintended binding and off-target effects. A medication from this drug class, pirtobrutinib was approved by the FDA for chronic lymphocytic …

us, ca (code pays fourni par la source)

Evaluation of real-world outcomes among CLL patients based on sequencing of BTKi and BCL2i therapies

Taral Patel, Rushir J. Choksi, Tejvir Singh, Aliakbar Dadla et autres

Abstract Background: Current first-line (1L) therapies for chronic lymphocytic leukemia (CLL) consist of Bruton tyrosine kinase inhibitors (BTKi) or B-cell lymphoma 2 inhibitors (BCL2i). However, many patients (pts) will require multiple therapies over the course of their treatment and often switch from …

us, ca (code pays fourni par la source)

527P Real-world study on rates of positivity for ESR1, PIK3CA, PTEN, and ATK1 among ER+/HER2- metastatic breast cancer patients

Stephan Rosenfeld, Suresh V. Reddy, R. Choksi, V. S. Gorantla et autres

us (code pays fourni par la source)

521P Real-world study on ESR1 positivity rate in relation to length of exposure on endocrine therapy +/- CDK4/6i

V. S. Gorantla, Stephan Rosenfeld, Suresh V. Reddy, R. Choksi et autres

us (code pays fourni par la source)

506P Real-world study on the significance of next generation sequencing testing for ESR1 in ER+/HER2 : Metastatic breast cancer patients after endocrine therapy progression

R. Choksi, V. S. Gorantla, Stephan Rosenfeld, Suresh V. Reddy et autres

us (code pays fourni par la source)

440eP Quality initiative for patients with HR+/HER2-, node-positive, early breast cancer at a high risk of recurrence

Fred J. Kudrik, Stephan Rosenfeld, S. Reganti, V. S. Gorantla et autres

us (code pays fourni par la source)